Regulatory
567 articles
FDA Adverse Event Monitoring System (AEMS): What Replaced MAUDE for Medical Devices
FDA replaces MAUDE with AEMS — unified adverse event dashboard, migration timeline, data limitations, and reporting changes for device manufacturers.
FDA 510(k) Clearances: Tracking, Timelines, and Decision Data
Track FDA 510(k) clearances, understand review timelines, interpret SE/NSE decisions, use the 510(k) database, and apply clearance statistics to your 2026 regulatory strategy.
FDA 510(k) Guidance Documents: Device-Specific Requirements and Special Controls
How to find and use FDA 510(k) guidance documents, Class II special controls, device-specific submission requirements, and the CDRH FY 2026 guidance agenda to prepare stronger premarket submissions.
FDA Medical Device Registration: Step-by-Step Process from Classification to Market
Step-by-step FDA medical device registration — classification, 510(k)/De Novo/PMA pathways, establishment registration, device listing, FY 2026 fees, and post-market obligations.
Dermal Fillers vs Cosmetics vs Medicines: Hong Kong Borderline Classification After GN-00
How Hong Kong classifies injectable dermal fillers at the borderline between medical devices, cosmetics, and medicines — and why the May 2026 GN-00 update matters for your product.
Hong Kong Dermal Filler MDACS Listing Strategy: LRP, Docs, Importers, Procurement
Guide to listing injectable dermal fillers under Hong Kong MDACS after the May 2026 GN-00 update: LRP, technical dossier, importer controls, adverse event reporting, and procurement.
Hong Kong MDACS GN-00 Update: Why Injectable Dermal Fillers Are Now Medical Devices
On 13 May 2026, Hong Kong MDD updated GN-00 to classify injectable dermal fillers as medical devices under MDACS. What changed, why it matters, and what manufacturers must do.
RPM Device Regulatory Pathway: FDA, CMS Reimbursement & EU MDR (2026)
RPM device regulation: FDA classification, CMS 2026 CPT codes (99445, 99470), reimbursement rates, SaMD, EU MDR pathway, and commercialization strategy for connected monitoring devices.
EU Digital Product Passport for Medical Devices: ESPR, Batteries, and UDI
Guide to EU Digital Product Passport requirements for medical devices, including ESPR scope, battery passports, UDI/EUDAMED links, standards, and timelines.
Liquid Biopsy and Multi-Cancer Early Detection (MCED) Tests: FDA, IVDR Regulatory Pathway
Regulatory guide to liquid biopsy and MCED tests, including FDA pathways, Breakthrough designation, companion diagnostics, EU IVDR classification, clinical evidence, and key market players.
Swissmedic 2026 PMS Focus Campaign: What Class IIa/IIb/III Manufacturers Must Prepare Now
Swissmedic 2026 PMS focus campaign guide for Class IIa, IIb, and III devices, covering PMS plans, PSURs, PMCF data, complaints, trend analysis, and preparation.
EUDAMED Mandatory Registration: May 28, 2026 Deadlines and UDI Steps
Guide to mandatory EUDAMED registration from May 28, 2026, including actor registration, UDI/device data, certificate linkage, legacy device deadlines, and action steps.
Health Canada REP and CESG Digital Submissions for Medical Devices
Prepare for mandatory REP and CESG submissions for Class II-IV medical device licences, including IMDRF ToC format, XML templates, workflow changes, and April 2026 scope.
FDA TEMPO Pilot for Digital Health Devices and CMS ACCESS
Guide to FDA's TEMPO pilot for digital health devices, enforcement discretion, real-world evidence, CMS ACCESS alignment, eligibility, and key dates.
FTC Blocks Edwards' $945M JenaValve Deal: Medical Device Antitrust
Analysis of the FTC injunction blocking Edwards' JenaValve acquisition, the TAVR-AR innovation market theory, court ruling, and medtech M&A implications.
Waters-BD Biosciences $18.8B Merger: Life Science Tools Deal Guide
Analysis of Waters' $18.8B BD Biosciences combination, covering deal structure, analytical platforms, diagnostics synergies and impact on device and IVD manufacturers.
Boston Scientific-Bolt $900M Deal: IVL Market and FDA Strategy
Analysis of Boston Scientific's up to $900M Bolt Medical acquisition, laser-based IVL technology, FDA 510(k) pathway, RESTORE and FRACTURE trials, Shockwave competition, and calcified artery market.
Stryker Inari Medical $4.9B Deal: VTE Thrombectomy Market Analysis
Stryker's $4.9B Inari Medical acquisition adds FlowTriever and ClotTriever platforms. Review deal structure, VTE thrombectomy competition, FDA pathways, and commercialization impact.
DePuy Synthes Gemtrack RF Tracking Deal: Orthopedic Robotics Impact
Analysis of DePuy Synthes' Gemtrack RF tracking deal, including VELYS strategy, competition with Mako and ROSA, J&J portfolio options, orthopedic robotics growth, and regulatory considerations.
IV-to-Subcutaneous Shift: OBDS Regulatory Strategy Guide (2026)
Analysis of the IV-to-subcutaneous shift in biologics, covering on-body delivery systems, OBDS combination product pathways, human factors, and market drivers.